2025-02-10 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
RGNX |
Sell
All
|
1.73% |
Assets Rebalanced
None
2025-02-07 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
RGNX
REGENXBIO Inc.
|
Buy |
10.01% |
4.46% |
2025-02-03 |
The percentage of cash held in the portfolio is:
89.99%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
FATE |
Sell
All
|
2.19% |
SGMO |
Sell
All
|
3.25% |
NTRA |
Sell
All
|
-0.64% |
Assets Rebalanced
None
2025-02-06 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
FATE
Fate Therapeutics, Inc.
|
Buy |
10.47% |
3.65% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
10.35% |
2.44% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
10.14% |
0.41% |
2025-01-31 |
RGNX
REGENXBIO Inc.
|
Buy |
9.99% |
4.46% |
2025-02-03 |
The percentage of cash held in the portfolio is:
59.06%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
BLFS |
Sell
All
|
-5.58% |
Assets Rebalanced
None
2025-02-03 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BLFS
BioLife Solutions, Inc.
|
Buy |
9.6% |
-3.5% |
2025-01-30 |
FATE
Fate Therapeutics, Inc.
|
Buy |
9.71% |
-5.11% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
10.24% |
0% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
10.28% |
0.37% |
2025-01-31 |
RGNX
REGENXBIO Inc.
|
Buy |
9.7% |
0% |
2025-02-03 |
The percentage of cash held in the portfolio is:
50.48%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
CPRX |
Sell
All
|
-5.84% |
TGTX |
Sell
All
|
-0.69% |
SENS |
Sell
All
|
-14.96% |
Assets Rebalanced
None
2025-01-31 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.2% |
-3.54% |
2025-01-27 |
TGTX
TG Therapeutics, Inc.
|
Buy |
9.98% |
4.51% |
2025-01-28 |
BLFS
BioLife Solutions, Inc.
|
Buy |
9.5% |
-2.12% |
2025-01-30 |
CPRX
Catalyst Pharmaceuticals, Inc.
|
Buy |
9.39% |
-3.21% |
2025-01-30 |
FATE
Fate Therapeutics, Inc.
|
Buy |
9.99% |
0% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.99% |
0% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
9.99% |
0% |
2025-01-31 |
The percentage of cash held in the portfolio is:
31.96%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
NUTX |
Sell
All
|
16.85% |
RGNX |
Sell
All
|
-0.63% |
Assets Rebalanced
None
2025-01-30 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NUTX
Nutex Health Inc.
|
Buy |
10.8% |
9.33% |
2025-01-24 |
RGNX
REGENXBIO Inc.
|
Buy |
9.35% |
-5.41% |
2025-01-24 |
SENS
Senseonics Holdings, Inc.
|
Buy |
8.88% |
-7.96% |
2025-01-27 |
TGTX
TG Therapeutics, Inc.
|
Buy |
10.1% |
4.54% |
2025-01-28 |
BLFS
BioLife Solutions, Inc.
|
Buy |
9.81% |
0% |
2025-01-30 |
CPRX
Catalyst Pharmaceuticals, Inc.
|
Buy |
9.81% |
0% |
2025-01-30 |
The percentage of cash held in the portfolio is:
41.25%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
SIGA |
Sell
All
|
-2.03% |
Assets Rebalanced
None
2025-01-29 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
SIGA
SIGA Technologies, Inc.
|
Buy |
9.58% |
-2.97% |
2025-01-23 |
NUTX
Nutex Health Inc.
|
Buy |
10.31% |
4.47% |
2025-01-24 |
RGNX
REGENXBIO Inc.
|
Buy |
9.43% |
-4.4% |
2025-01-24 |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.46% |
-1.77% |
2025-01-27 |
TGTX
TG Therapeutics, Inc.
|
Buy |
10.11% |
4.79% |
2025-01-28 |
The percentage of cash held in the portfolio is:
51.11%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
AGEN |
Sell
All
|
-7.05% |
BHVN |
Sell
All
|
-1.69% |
TVTX |
Sell
All
|
8.43% |
DNLI |
Sell
All
|
2% |
Assets Rebalanced
None
2025-01-28 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AGEN
Agenus Inc.
|
Buy |
9.36% |
-6.01% |
2025-01-22 |
BHVN
Biohaven Ltd.
|
Buy |
10.19% |
2.31% |
2025-01-22 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
10.3% |
3.44% |
2025-01-22 |
DNLI
Denali Therapeutics Inc.
|
Buy |
10.02% |
0.65% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
9.92% |
-0.78% |
2025-01-23 |
NUTX
Nutex Health Inc.
|
Buy |
9.87% |
-1.22% |
2025-01-24 |
RGNX
REGENXBIO Inc.
|
Buy |
9.64% |
-3.52% |
2025-01-24 |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.15% |
-6.19% |
2025-01-27 |
TGTX
TG Therapeutics, Inc.
|
Buy |
9.77% |
0% |
2025-01-28 |
The percentage of cash held in the portfolio is:
11.77%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-27 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AGEN
Agenus Inc.
|
Buy |
9.19% |
-6.79% |
2025-01-22 |
BHVN
Biohaven Ltd.
|
Buy |
9.94% |
0.77% |
2025-01-22 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
10.29% |
4.37% |
2025-01-22 |
DNLI
Denali Therapeutics Inc.
|
Buy |
9.51% |
-3.56% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
10% |
0.94% |
2025-01-23 |
NUTX
Nutex Health Inc.
|
Buy |
10.28% |
3.86% |
2025-01-24 |
RGNX
REGENXBIO Inc.
|
Buy |
9.81% |
-0.88% |
2025-01-24 |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.66% |
0% |
2025-01-27 |
The percentage of cash held in the portfolio is:
21.33%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
GKOS |
Sell
All
|
2.45% |
Assets Rebalanced
None
2025-01-24 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
GKOS
Glaukos Corporation
|
Buy |
9.1% |
3.09% |
2025-01-20 |
AGEN
Agenus Inc.
|
Buy |
9.55% |
-1.83% |
2025-01-22 |
BHVN
Biohaven Ltd.
|
Buy |
10.15% |
4.3% |
2025-01-22 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
10.41% |
6.94% |
2025-01-22 |
DNLI
Denali Therapeutics Inc.
|
Buy |
9.83% |
1.04% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
9.89% |
1.25% |
2025-01-23 |
NUTX
Nutex Health Inc.
|
Buy |
9.77% |
0% |
2025-01-24 |
RGNX
REGENXBIO Inc.
|
Buy |
9.77% |
0% |
2025-01-24 |
The percentage of cash held in the portfolio is:
21.53%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-23 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
GKOS
Glaukos Corporation
|
Buy |
9.14% |
2.39% |
2025-01-20 |
AGEN
Agenus Inc.
|
Buy |
9.41% |
-4.44% |
2025-01-22 |
BHVN
Biohaven Ltd.
|
Buy |
10.23% |
3.92% |
2025-01-22 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
9.84% |
0% |
2025-01-22 |
DNLI
Denali Therapeutics Inc.
|
Buy |
9.96% |
1.17% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
9.88% |
0% |
2025-01-23 |
The percentage of cash held in the portfolio is:
41.54%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
MD |
Sell
All
|
0.5% |
MDXG |
Sell
All
|
1.93% |
NVRO |
Sell
All
|
15.57% |
LGND |
Sell
All
|
5.06% |
AXSM |
Sell
All
|
9.09% |
Assets Rebalanced
None
2025-01-22 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.38% |
0% |
2025-01-16 |
MDXG
MiMedx Group, Inc.
|
Buy |
9.72% |
3.63% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
10.35% |
10.38% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
9.98% |
6.42% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
9.62% |
2.59% |
2025-01-16 |
GKOS
Glaukos Corporation
|
Buy |
9.19% |
1.89% |
2025-01-20 |
AGEN
Agenus Inc.
|
Buy |
9.94% |
0% |
2025-01-22 |
BHVN
Biohaven Ltd.
|
Buy |
9.94% |
0% |
2025-01-22 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
9.94% |
0% |
2025-01-22 |
DNLI
Denali Therapeutics Inc.
|
Buy |
9.94% |
0% |
2025-01-22 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
NUTX |
Sell
All
|
20.31% |
ACRS |
Sell
All
|
4% |
Assets Rebalanced
None
2025-01-21 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NUTX
Nutex Health Inc.
|
Buy |
11.12% |
18.16% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.68% |
2.8% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.44% |
-1.14% |
2025-01-16 |
MDXG
MiMedx Group, Inc.
|
Buy |
9.87% |
3.4% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
10.29% |
7.78% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
9.69% |
1.46% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
9.36% |
-1.94% |
2025-01-16 |
GKOS
Glaukos Corporation
|
Buy |
9.18% |
0% |
2025-01-20 |
The percentage of cash held in the portfolio is:
21.37%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
AXGN |
Sell
All
|
NA |
INSM |
Sell
All
|
NA |
Assets Rebalanced
None
2025-01-20 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AXGN
AxoGen, Inc.
|
Buy |
9.4% |
-0.88% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
9.97% |
5.19% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
11.12% |
18.16% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.68% |
2.8% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.44% |
-1.14% |
2025-01-16 |
MDXG
MiMedx Group, Inc.
|
Buy |
9.87% |
3.4% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
10.29% |
7.78% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
9.69% |
1.46% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
9.36% |
-1.94% |
2025-01-16 |
GKOS
Glaukos Corporation
|
Buy |
9.18% |
0% |
2025-01-20 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ESPR |
Sell
All
|
-5.56% |
Assets Rebalanced
None
2025-01-16 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.48% |
-5.56% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
9.99% |
2.63% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
9.92% |
1.84% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
9.88% |
2.16% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.71% |
0.4% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.81% |
0% |
2025-01-16 |
MDXG
MiMedx Group, Inc.
|
Buy |
9.81% |
0% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
9.81% |
0% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
9.81% |
0% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
9.81% |
0% |
2025-01-16 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ARDX |
Sell
All
|
0.19% |
AORT |
Sell
All
|
-0.56% |
Assets Rebalanced
None
2025-01-15 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AORT
Artivion, Inc.
|
Buy |
9.88% |
-1.82% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
10.59% |
5.24% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.63% |
-4.27% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
9.76% |
-0.05% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
9.67% |
-0.93% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
9.69% |
0% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.69% |
0% |
2025-01-15 |
The percentage of cash held in the portfolio is:
31.08%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
MDRX |
Sell
All
|
-6.67% |
Assets Rebalanced
None
2025-01-14 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.7% |
-2.56% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
9.66% |
-2.94% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
10.96% |
10.11% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.7% |
-2.56% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
9.66% |
0% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
9.66% |
0% |
2025-01-14 |
The percentage of cash held in the portfolio is:
40.65%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
TNDM |
Sell
All
|
-3.07% |
BLUE |
Sell
All
|
-14.42% |
Assets Rebalanced
None
2025-01-13 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.7% |
-3.63% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
8.59% |
-14.72% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.82% |
-2.46% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
9.95% |
-1.16% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
9.56% |
-5.06% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
10.08% |
0% |
2025-01-13 |
The percentage of cash held in the portfolio is:
42.3%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-09 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
10% |
0.36% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
8.5% |
-14.72% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.72% |
-2.46% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
9.97% |
0% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
9.97% |
0% |
2025-01-09 |
The percentage of cash held in the portfolio is:
51.84%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-08 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.82% |
-0.82% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
9% |
-9.07% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
9.9% |
0% |
2025-01-08 |
The percentage of cash held in the portfolio is:
71.29%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-07 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.8% |
0% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
9.8% |
0% |
2025-01-07 |
The percentage of cash held in the portfolio is:
80.4%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-12-12 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
PCRX |
Sell
All
|
6.5% |
Assets Rebalanced
None
2024-12-10 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PCRX
Pacira BioSciences, Inc.
|
Buy |
9.83% |
0% |
2024-12-05 |
The percentage of cash held in the portfolio is:
90.17%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
ESPR |
Sell
All
|
23.55% |
RVNC |
Sell
All
|
-27.34% |
Assets Rebalanced
None
2024-12-05 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
11.38% |
18.06% |
2024-12-03 |
RVNC
Revance Therapeutics, Inc.
|
Buy |
9.62% |
0% |
2024-12-05 |
PCRX
Pacira BioSciences, Inc.
|
Buy |
9.62% |
0% |
2024-12-05 |
The percentage of cash held in the portfolio is:
69.37%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ARWR |
Sell
All
|
-11.63% |
Assets Rebalanced
None
2024-12-04 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.72% |
-0.31% |
2024-11-28 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
10.12% |
4.84% |
2024-12-03 |
The percentage of cash held in the portfolio is:
80.16%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
APLS |
Sell
All
|
6.13% |
MGNX |
Sell
All
|
1.18% |
Assets Rebalanced
None
2024-12-03 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.52% |
8.55% |
2024-11-27 |
MGNX
MacroGenics, Inc.
|
Buy |
10.52% |
8.53% |
2024-11-27 |
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.76% |
0.73% |
2024-11-28 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.6% |
0% |
2024-12-03 |
The percentage of cash held in the portfolio is:
59.6%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
FATE |
Sell
All
|
-6.62% |
Assets Rebalanced
None
2024-11-28 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.14% |
4.63% |
2024-11-27 |
MGNX
MacroGenics, Inc.
|
Buy |
10.37% |
7.06% |
2024-11-27 |
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.69% |
0% |
2024-11-28 |
FATE
Fate Therapeutics, Inc.
|
Buy |
9.69% |
0% |
2024-11-28 |
The percentage of cash held in the portfolio is:
60.12%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-11-27 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.8% |
0% |
2024-11-27 |
MGNX
MacroGenics, Inc.
|
Buy |
9.8% |
0% |
2024-11-27 |
The percentage of cash held in the portfolio is:
80.4%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-11-19 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
MDRX |
Sell
All
|
-4.98% |
Assets Rebalanced
None
2024-11-18 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
10.39% |
-5.24% |
2024-11-12 |
The percentage of cash held in the portfolio is:
89.61%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
RGEN |
Sell
All
|
-17.11% |
TGTX |
Sell
All
|
-3.9% |
ITGR |
Sell
All
|
-2.62% |
FGEN |
Sell
All
|
3.72% |
Assets Rebalanced
None
2024-11-15 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ITGR
Integer Holdings Corporation
|
Buy |
9.46% |
-1.41% |
2024-11-11 |
FGEN
FibroGen, Inc.
|
Buy |
10.99% |
14.55% |
2024-11-11 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
10.23% |
-3.91% |
2024-11-12 |
TGTX
TG Therapeutics, Inc.
|
Buy |
10.69% |
0.34% |
2024-11-12 |
RGEN
Repligen Corporation
|
Buy |
9.17% |
-5.34% |
2024-11-14 |
The percentage of cash held in the portfolio is:
49.46%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
SAGE |
Sell
All
|
-15.03% |
CHRS |
Sell
All
|
-5.73% |
Assets Rebalanced
None